QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:BCAB

BioAtla (BCAB) Stock Forecast, Price & News

$1.72
-0.07 (-3.91%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.67
$1.82
50-Day Range
$1.72
$3.07
52-Week Range
$1.67
$11.73
Volume
294,936 shs
Average Volume
522,017 shs
Market Capitalization
$82.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

BioAtla MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
762.4% Upside
$14.83 Price Target
Short Interest
Bearish
10.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.14mentions of BioAtla in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$5,080 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.82) to ($2.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

721st out of 962 stocks

Biological Products, Except Diagnostic Industry

117th out of 161 stocks


BCAB stock logo

About BioAtla (NASDAQ:BCAB) Stock

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BCAB Price History

BCAB Stock News Headlines

Analyst Ratings for BioAtla
Holding NVDA? Read This Now
NVDA is likely not the best buy for A.I. investors. 50-year Wall Street veteran Marc Chaikin reveals what to buy instead. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
H.C. Wainwright Reaffirms Their Buy Rating on BioAtla (BCAB)
Where BioAtla Stands With Analysts
H.C. Wainwright Keeps Their Buy Rating on BioAtla (BCAB)
BioAtla (BCAB) Receives a Buy from JMP Securities
BioAtla (BCAB) Receives a Buy from BTIG
Bioatla (BCAB) Earnings Dates & Reports
See More Headlines
Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

BCAB Company Calendar

Last Earnings
8/01/2023
Today
9/25/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCAB
Fax
N/A
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.83
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+802.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-106,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$3.79 per share

Miscellaneous

Free Float
43,797,000
Market Cap
$81.26 million
Optionable
Not Optionable
Beta
0.28
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Jay M. Short Ph.D. (Age 65)
    Co-Founder, CEO & Chairman
    Comp: $1.06M
  • Mr. Richard A. WaldronMr. Richard A. Waldron (Age 69)
    Sr. VP & CFO
    Comp: $617.62k
  • Dr. Eric L. Sievers M.D. (Age 59)
    Chief Medical Officer
    Comp: $608.18k
  • Mr. Christian J. VasquezMr. Christian J. Vasquez (Age 47)
    Sr. VP of Fin., Corp. Controller & Sec.
    Comp: $408.75k
  • Lisa M. Pelton
    Accounting Mang.
  • Ms. Susie Melody
    Sr. VP of HR
  • Dr. Cathy Chang Ph.D.
    Sr. VP of R&D
  • Dr. Gerhard Frey Ph.D.
    Sr. VP of Technology Devel.
  • Ms. Monica Sullivan
    Sr. VP of Intellectual Property & Contracts
  • Ms. Sheri Lydick
    Chief Commercial Officer













BCAB Stock - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCAB shares.
View BCAB analyst ratings
or view top-rated stocks.

What is BioAtla's stock price forecast for 2023?

6 analysts have issued twelve-month target prices for BioAtla's stock. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they expect the company's stock price to reach $14.83 in the next twelve months. This suggests a possible upside of 772.6% from the stock's current price.
View analysts price targets for BCAB
or view top-rated stocks among Wall Street analysts.

How have BCAB shares performed in 2023?

BioAtla's stock was trading at $8.25 at the start of the year. Since then, BCAB shares have decreased by 79.4% and is now trading at $1.6999.
View the best growth stocks for 2023 here
.

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our BCAB earnings forecast
.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) posted its earnings results on Tuesday, August, 1st. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.13.

What ETF holds BioAtla's stock ?

Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio.

When did BioAtla IPO?

(BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

What is BioAtla's stock symbol?

BioAtla trades on the NASDAQ under the ticker symbol "BCAB."

Who are BioAtla's major shareholders?

BioAtla's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.71%), Wasatch Advisors LP (3.15%), Geode Capital Management LLC (1.74%), State Street Corp (1.49%), Renaissance Technologies LLC (1.44%) and Vontobel Holding Ltd. (1.19%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn.
View institutional ownership trends
.

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioAtla's stock price today?

One share of BCAB stock can currently be purchased for approximately $1.70.

How much money does BioAtla make?

BioAtla (NASDAQ:BCAB) has a market capitalization of $81.26 million and generates $250,000.00 in revenue each year. The company earns $-106,480,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How can I contact BioAtla?

The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com.

This page (NASDAQ:BCAB) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -